Jazz Pharmaceuticals plc (JAZZ) announced that its Co-Founder, Chairperson, and Chief Executive Officer, Bruce Cozadd, has decided to retire from his CEO position once a new leader is appointed, anticipated by late 2025. Cozadd will maintain his role as Chairperson of the Board of Directors.
The Board has launched a formal search to identify a new Chief Executive Officer, with the search expected to conclude within 12 months.
Jazz Pharmaceuticals reaffirmed its financial outlook, projecting full-year 2024 total revenues between $4.0 billion and $4.1 billion. Analysts surveyed by Thomson Reuters forecast the company's 2024 fiscal year revenues at approximately $4.04 billion, with these estimates generally excluding special items.
